Painless nerve growth factor similar peptide and application thereof

By designing a NGF-like peptide that is strongly bound to Trk A, the problem of pain response in NGF treatment is solved, and the painless and effective nerve growth promotion effect is achieved, which is suitable for the treatment of peripheral nerve damage.

CN118909073AActive Publication Date: 2024-11-08SHENZHEN SECOND PEOPLES HOSPITAL (SHENZHEN INST OF TRANSLATIONAL MEDICINE)
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411098655.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-12
Publication Date
2024-11-08
Estimated Expiration
2044-08-12

AI Technical Summary

Technical Problem

Existing nerve growth factor (NGF) often causes pain response when treating peripheral nerve damage, and existing painless NGF drugs are complex in preparation, high in price, addictive or low target specificity, and cannot be widely used.

Method used

A painless nerve growth factor-like peptide was designed to synthesize small-molecular peptides with strong affinity and good biological activity by performing amino acid mutations on the key region Loop I sequence of NGF and Trk A, using solid phase synthesis method and Purification was carried out by HPLC and other technologies to avoid painful reactions caused by NGF.

Benefits of technology

This painless nerve growth factor-like peptide can effectively penetrate into cells, promote cell growth, is highly dose-dependent, and does not cause pain and allergic reactions. It overcomes the pain side effects in NGF treatment and has the characteristics of simple structure and significant effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909073A_ABST
    Figure CN118909073A_ABST
Patent Text Reader

Abstract

The invention discloses a painless nerve growth factor similar peptide and application. The amino acid sequences of the painless nerve growth factor similar peptide are as shown in SEQ ID NO.1-7. The painless nerve growth factor similar peptide has good biological activity, has strong affinity with Trk A, can well permeate into cells and promote cell growth to present dose dependence; in addition, the administration dosage for promoting cell growth is minimum. Animal pain and anaphylaxis are not caused, and the pain reaction caused by NGF during administration can be overcome.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application belongs to the field of synthetic biology technology, and in particular relates to a painless nerve growth factor-like peptide and its application. Background Art

[0002] Peripheral nerve injury (PNI) is mainly caused by falling from a height, traffic accidents, sharp cutting, limb ischemia and spasm, etc., which cause neuronal damage and destruction of nerve structure, resulting in motor, sensory and autonomic dysfunction of patients' limbs, seriously affecting their quality of life. At present, microsurgery or autologous nerve transplantation are mainly used in the clinic for the treatment of this disease. In addition, exogenous administration of biomaterials, seed cells and / or nutritional factors has also been well verified in the repair of animal PNI models. Although these measures can restore the structure and function of damaged peripheral nerves to varying degrees, patients will experience varying degrees of acute and chronic pain reactions after surgery, which are manifested as persistent, paroxysmal or pulling-like tingling in the surgical area, which is particularly obvious at night.

[0003] Nerve growth factor (NGF) is a secretory protein that promotes nerve growth and nourishes nerves. It is widely expressed in various tissues and cells, including the brain, ganglia, skeletal muscle, glial cells, Schwann cells, etc. In vitro, NGF can promote the growth and development of sympathetic and sensory neurons; in vivo, exogenous administration of NGF can promote early embryonic development. In addition, it has a significant effect on improving the regeneration of axons and myelin sheaths and the recovery of motor function after PNI. In addition, NGF is also widely used in the treatment of hypoxic-ischemic encephalopathy, spinal cord injury and diabetic peripheral neuropathy (DPN). However, after PNI, the expression level of endogenous NGF is abnormally increased, and in the process of Phase III clinical trials for the treatment of DPN, large doses of NGF injection are prone to cause abnormal pain at the injection site, accompanied by side effects such as myalgia and arthralgia, and this hyperalgesia symptom lasts for up to 7 weeks and is dose-dependent. Therefore, how to solve the pain response caused by NGF is the focus of scientific attention at present.

[0004] The painless NGF drugs that have been developed so far all have some defects. For example, the preparation process of NGF-targeted monoclonal antibodies is complicated and expensive, and long-term injections are addictive and can cause neuropathy and joint damage. The target specificity of small molecule compounds is not high, and the effects of pain relief and promoting nerve growth are not significant, and they may even induce cell apoptosis. NGF mutants are mainly obtained from Middle Eastern patients with hereditary sensory and autonomic neuropathy. Therefore, the sources of acquisition are relatively limited and cannot be widely used. Based on this, it is urgent to have a simple structure, significant effect and painless NGF peptide drug. Summary of the invention

[0005] The embodiments of the present application provide a painless nerve growth factor-like peptide and its application. The painless nerve growth factor-like peptide of the present application has good biological activity, has a strong affinity with Trk A, can penetrate into cells well and promote cell growth in a dose-dependent manner; in addition, the dosage for promoting cell growth is small, will not cause pain allergic reactions in animals, and can overcome the pain reaction caused by NGF when administered.

[0006] In a first aspect, the embodiments of the present application provide a pain-free nerve growth factor-like peptide, the amino acid sequence of the pain-free nerve growth factor-like peptide is shown in SEQ ID NO.1-7.

[0007] Nerve growth factor (NGF) includes a hairpin loop and an N-terminus. Loop I is the first hairpin loop region in the NGF molecule, usually located near the N-terminus of the protein. Loop IV is another key hairpin loop region in the NGF molecule, usually located near the C-terminus of the protein. The N-terminus of NGF refers to the region between the first amino acid residue of the protein chain and the first domain (usually Loop I).

[0008] TrkA (Tropomyosin receptor kinase A) is a high-affinity receptor for NGF (Nerve Growth Factor), and the interaction between the two plays a key role in the development and functional maintenance of the nervous system. The binding of NGF to TrkA is highly specific. NGF binds to the extracellular domain of TrkA through its domains (including Loop I and Loop IV) to form a stable complex. This binding triggers the dimerization of TrkA, which is the first step in signal transduction.

[0009] According to crystallography and molecular structure simulation, the hairpin Loop I, Loop IV and N-term of the NGF-targeted monoclonal antibody are the key regions that bind to Trk A and mediate various downstream intracellular signal cascades. Among these three regions, studies have found that Loop I is exposed outward in the form of β-turn and a small molecule peptide with this sequence structure can increase the effect of nerve growth by 10 times. Therefore, this region has the greatest biological effect.

[0010] Based on the Loop I sequence (TTATDIKGKEVMVL) that binds human NGF to Trk A, we designed small molecule peptides with different lengths and site mutations (such as Figure 1 , 12 designed peptides were synthesized, purified and identified by solid phase synthesis, HPLC column and mass spectrometry. Fluorescence polarization (FP), cell membrane penetration and CCK-8 were used to screen multiple peptides with strong binding to Trk A, good intracellular penetration and strong activity, and the best one was found.

[0011] In some embodiments, the amino acid sequence of the pain-free nerve growth factor-like peptide is shown as SEQ ID NO.7.

[0012] The research found that the painless nerve growth factor-like peptide with an amino acid sequence as shown in SEQ ID NO.7 is the one that binds strongly to TrkA, penetrates cells best and has the strongest activity.

[0013] In some embodiments, the polypeptide is obtained by any one of solid phase synthesis, liquid phase polypeptide synthesis, genetic engineering or fermentation.

[0014] In some embodiments, in the process of obtaining the pain-free nerve growth factor analog peptide by solid phase synthesis, the equivalent of each amino acid is between 2-5.

[0015] In the second aspect, the present application example uses a solid phase synthesis method, which can be used for small-scale synthesis of small molecule polypeptide sequences as shown in any one of SEQ ID NO.1-7

[0016] In a third aspect, an embodiment of the present application provides a nucleic acid molecule for large-scale encoding of an amino acid sequence as shown in any one of SEQ ID NOs. 1-7.

[0017] In a fourth aspect, an embodiment of the present application provides a recombinant plasmid, wherein the recombinant plasmid contains the nucleic acid molecule described in the second aspect.

[0018] In a fifth aspect, an embodiment of the present application provides a transformant, which comprises the nucleic acid molecule of the third aspect or the recombinant plasmid of the fourth aspect.

[0019] In some embodiments, the transformant is Escherichia coli.

[0020] In a sixth aspect, the present application provides a drug, comprising:

[0021] The pain-free nerve growth factor-like peptide of the first aspect; and

[0022] Pharmaceutically acceptable adjuvants.

[0023] The pharmaceutically acceptable adjuvant may be various buffers or various additives.

[0024] In some embodiments, the mass concentration of the pain-free nerve growth factor analog peptide in the drug is 5 ng / mL to 50 μg / mL.

[0025] In a fifth aspect, the embodiments of the present application provide an application of the pain-free nerve growth factor-like peptide of the first aspect, the nucleic acid molecule of the second aspect, the recombinant plasmid of the third aspect, or the transformant of the fourth aspect in the preparation of peripheral nerve injury drugs for analgesia.

[0026] The embodiments of the present application have at least the following beneficial effects:

[0027] The painless nerve growth factor-like peptide of the present application has good biological activity, has a strong affinity with Trk A, can penetrate into cells well and promote cell growth in a dose-dependent manner; in addition, the dosage for promoting cell growth is minimal. It will not cause pain allergic reactions in animals and can overcome the pain reaction caused by NGF when administered.

[0028] The painless nerve growth factor-like peptide prepared in the present application complies with the concept of green environmental protection, does not use environmentally friendly chemical reagents during the synthesis process, and has high safety. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] In order to more clearly illustrate the technical solutions of the embodiments of the present application, the drawings required for use in the embodiments of the present application will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0030] Figure 1 The graph shows the binding strength of the small molecule peptide of the example of the present application to Trk A.

[0031] Figure 2The diagram shows the effect of cell uptake of each peptide linked to FITC in the cell according to the example of the present application.

[0032] Figure 3 A graph showing the effects of different small molecule peptides and cell survival rate according to the examples of the present application is shown.

[0033] Figure 4 The figure shows that NPL7 according to the example of the present application promotes the regeneration of nerves after PNI.

[0034] Figure 5 A graph showing the intensity of pain hypersensitivity caused by NPL7 of an embodiment of the present application when subjected to mechanical or thermal stimulation. DETAILED DESCRIPTION

[0035] In order to make the invention purpose, technical solution and beneficial technical effect of the present application clearer, the present application is described in detail below in conjunction with specific embodiments. It should be understood that the embodiments described in this specification are only for explaining the present application, not for limiting the present application.

[0036] For simplicity, only some numerical ranges are explicitly disclosed herein. However, any lower limit can be combined with any upper limit to form an unambiguous range; and any lower limit can be combined with other lower limits to form an unambiguous range, and any upper limit can be combined with any other upper limit to form an unambiguous range. In addition, although not explicitly stated, each point or single value between the range endpoints is included in the range. Thus, each point or single value can be combined with any other point or single value as its own lower limit or upper limit or with other lower limits or upper limits to form an unambiguous range.

[0037] In the description of this article, it should be noted that, unless otherwise specified, "above" and "below" are inclusive of the number itself, and "several" in "one or several" means two or more.

[0038] The above invention summary of the present application is not intended to describe each disclosed embodiment or each implementation in the present application. The following description more specifically illustrates exemplary embodiments. In many places throughout the application, guidance is provided by a series of examples, which can be used in various combinations. In each example, the enumeration is only used as a representative group and should be interpreted as exhaustive.

[0039] The following examples describe the disclosure of the present application in more detail, and these examples are intended for illustrative purposes only, as various modifications and variations within the scope of the disclosure of the present application are apparent to those skilled in the art. Unless otherwise stated, all percentages reported in the following examples are by weight, and all reagents used in the examples are commercially available or synthesized according to conventional methods and can be used directly without further processing, and the instruments used in the examples are commercially available.

[0040] Example 1 Preparation and purification of painless nerve growth factor-like peptide

[0041] According to the mass of each pre-synthesized peptide, a certain loading degree of Rink Amide-MBHA Resin (Product No.: XW0243104183702, Jier Biochemical Co., Ltd., Shanghai, China) was weighed and transferred to the peptide receiving tube, and dimethylformamide (DMF) was added and nitrogen (N 2 ) for 20 min; prepare 50% morpholine solution (morpholine:DMF=1:1) and add it to the peptide tube, pass N 2 Blow for 30 minutes, repeat twice, and wash with dichloromethane (DCM) and DMF alternately for 3 times; the amount of different amino acids used is calculated according to 2-5 equivalents, and 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU) and diisopropylethylamine (DIPEA) are added and mixed. The molar ratio of 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU) and diisopropylethylamine (DIPEA) is 3.5:1. It is fully dissolved in an appropriate amount of DMF solution, and then added to the peptide receiving tube and stirred at N 2 The reaction was carried out under the condition of blowing for 1.5-2h. According to the amino acid sequence of each peptide, the corresponding amino acids of each peptide were connected in sequence according to the above steps. After the last amino acid was connected, it was concentrated with methanol for 5min and N 2 Blow to dry thoroughly.

[0042] The solid phase synthesized peptide was separated from the resin using a shearing solution (trifluoroacetic acid (TFA): triisopropylsilane: purified water = 95:2.5:2.5). 2After carefully blowing off TFA, add ether and ultracentrifuge for 5 minutes; after carefully removing the ether, add 50% acetonitrile solution to the centrifuge tube containing the polypeptide, and after the polypeptide is fully dissolved in acetonitrile, filter it using a 0.22μm filter membrane; start the high performance liquid chromatography (HPLC), inject, set the instrument parameters and time program, and collect samples with different peaks at different time points in the instrument during the execution of the program; use a mass spectrometer to identify the collected samples and confirm the target polypeptide according to the molecular weight of each polypeptide, collect the target polypeptide solution separated by HPLC, and then use liquid nitrogen to freeze the polypeptide solution and put it into a freeze dryer to obtain purified polypeptide powder, which is stored at -20℃ for a long time.

[0043] By these methods, amino acid sequences including linear polypeptides shown in SEQ ID No. 1-7 and 5 additional ones can be obtained, as shown in Table 1.

[0044] Table 1

[0045] Peptide name Peptide sequence NPLa TTATDIKGKEVMVL Nb TTATDIKGKEVM NPL ATDIKCKEK NPL TDIKGKEVM NPLe KKE NPL1 TDIKGKDVM NPL2 TDIKGKEKM NPL3 TDIKEKEVM NPL4 TDIKDKEVM NPL5 TDIKCKEVM NPL6 TDIKCKEDM NPL7 TDIKCKEKM

[0046] Example 2

[0047] Fluorescence polarization test (FP): According to the literature "Fluorescence Polarization Measurement System Using a Liquid Crystal Layer and an Image Sensor", the above 12 amino acid sequences were tested by fluorescence polarization test, and the following results were obtained: Figure 1 Results shown.

[0048] In the FP experiment Figure 1 The results show that NPL a -NPL 7 The binding constants (Kd) of these 12 peptides with Trk A are 88.3nM, 87.5nM, 107.0nM, 182.4nM, 146.4nM, 97.0nM, 350.8nM, 585.4nM, 135.2nM, 136.6nM, 299.4nM and 24.0nM, respectively. The Kd values ​​of each linear peptide with Trk A are all in the nM level, indicating that they bind strongly to Trk A. Among them, NPL 7 The Kd value is the smallest, but it is similar to NPL a , NPL b , NPL 1 The numerical difference is small. In addition, NPL c 、NPL 4 and NPL 5 The Kd values ​​of the proteins were all less than 150 nM, and further screening was required through membrane penetration and activity experiments.

[0049] Cell penetration assay (IF): According to the literature "Reversible stapling of unprotected peptides via chemoselective methionine bis-alkylation / dealkylation", the above 12 amino acid sequences were tested by fluorescence polarization assay, and the following results were obtained: Figure 2 Results shown.

[0050] In cell membrane permeation experiments Figure 2 The results showed that a certain concentration of linear peptides with FITC was added to the cell culture medium to a final concentration of 5 μM. After culturing PC12 cells for 4 hours, the cells were fixed and the nuclei were stained with DAPI. The intensity of green fluorescence emitted by the cells was observed under a laser confocal microscope. The IF results showed that the amount of FITC linear peptides taken up by the cells varied. Compared with the normal group, the cells took up NPL a 、NPL d 、NPL 6 and NPL 7 The amounts were relatively large, with values ​​of 165.28±26.3%, 253.18±36.5%, 247.16±24.6% and 355.16±41.8% respectively. Compared with other linear peptides, the fluorescence emitted by these four polypeptides in PC12 cells was stronger. Therefore, these amino acid sequences could easily penetrate the membrane and then quickly penetrate into the cells to exert their drug effects.

[0051] Cell survival rate detection: The CCK-8 kit of Yisheng Biotechnology (Shanghai) Co., Ltd. was used to detect the cell survival rate of the above 12 amino acid sequences. Different linear peptides with gradient concentrations were added to PC12 cell culture medium (89% DMEM high glucose medium + 10% fetal bovine serum + 1% penicillin / streptomycin) for 24 hours, and the survival rate of cells in different groups was detected by CCK-8. The results are as follows: Figure 3 Results shown.

[0052] NPL c 、NPL 5 and NPL 7 Cell survival ratio of any group = NPL c 、NPL 5 and NPL 7 Cell survival rate of any group / cell survival rate of NPL group

[0053] Figure 3 The experimental results show that NPL c 、NPL 5 and NPL 7The cell growth promoting effect increased with the increase of dose, and their respective optimal administration concentrations were 400nM, 200nM and 100nM.

[0054] In summary, through the above analysis, we get NPL 7 It has a strong affinity for Trk A, can penetrate into cells well and promote cell growth in a dose-dependent manner; in addition, the dosage required to promote cell growth is minimal.

[0055] Animal model experiments:

[0056] The sciatic nerve compression model was established using adult SD rats and divided into three groups: PNI group, NPL group 7 The NGF group was set as a positive control and can be compared with the NPL in the efficacy and analgesia evaluation. 7 By contrast, NPL 7 Whether it is possible to overcome the pain response induced by NGF while retaining its biological activity. In addition, in order to observe the morphology and function of the sciatic nerve of normal SD rats, we only exposed their sciatic nerves and set them as the Sham group. Different drugs were given to different groups, among which NPL 7 The group was injected orally with 10 μL of NPL 7 The NGF group was injected with 10 μL of NGF (8 ng / μL) in situ, and both groups were given the drug for 21 days, while the PNI group was injected with the same volume and number of days of normal saline in situ. Then the animals in each group were killed, and their sciatic nerve tissues were collected for pathological sectioning and staining.

[0057] Figure 4 .NPL 7 Promoting nerve regeneration after PNI: A shows H&E staining of nerves in each group; B shows NF-200 and MBP fluorescence staining of nerves in each group, scale = 100 μm; C shows the density of nerve fibers in each group; D and E show the positive areas of nerves in each group stained with NF-200 and MBP. ** P<0.01, *** P<0.001, P>0.05 (ns). The sciatic nerve tissues of the animals in each group were stained after being sacrificed. The results of H&E staining showed that the nerve fibers in the PNI group grew sparsely and had a lower density, while those in the NPL group had 7 or NGF treatment, the density of newborn nerve fibers increased significantly ( Figure 4 The staining results of NF-200 and MBP also showed that the number of axons and myelin sheaths in the PNI group was small and their arrangement was disordered. 7 Or NGF can significantly increase their number and make them orderly ( Figure 4 B, D and E). Therefore, NPL7 The effect of promoting nerve regeneration after PNI is similar to that of NGF. 7 The effect of promoting nerve fiber growth, axon and myelin regeneration is comparable to that of NGF, indicating that the modified NPL 7 Still retains the biological activity of NGF.

[0058] Pain assessment: Low, medium and high doses of NPL were injected into the soles of normal Balb / c mice. 7 Or NGF (concentrations were 0.05ug / kg, 0.5ug / kg, and 5ug / kg, respectively), and the mechanical stimulation paw withdrawal threshold and paw withdrawal latency were tested using a Von Frey analgesia and a hot plate instrument before administration (marked as 0min) and 15min, 30min, 45min, and 60min after administration, respectively.

[0059] Figure 5 The results show that at different concentrations of NPL 7 It does not induce pain hypersensitivity in response to mechanical or thermal stimulation. (AC) Von Frey fiber test Balb / c mice were injected with 0.05 μg / kg (low), 0.5 μg / kg (medium) and 5 μg / kg (high) doses of NPL in the plantar 7 or NGF, the changes in mechanical withdrawal threshold over time; (DE) to explore NPL 7 Effects of different doses of NGF on the mechanical withdrawal reflex threshold of mice; (FH) Hot plate test of Balb / c mice injected with 0.05μg / kg (low), 0.5μg / kg (medium) and 5μg / kg (high) doses of NPL in the sole of the foot 7 or NGF, the changes in paw withdrawal latency over time; (IJ) to explore the NPL 7 Or the effect of NGF at different doses on the paw withdrawal latency of mice, * P<0.05, ** P<0.01, *** P<0.001.

[0060] The experimental results showed that under the same dose conditions, injection of NPL 7 After that, the mechanical withdrawal reflex threshold of mice gradually decreased over time, while the injection of NGF had little effect on the mechanical withdrawal reflex threshold of mice ( Figure 5 AC). In addition, the comparative analysis results of drug gradient concentrations showed that the mechanical withdrawal reflex threshold of mice did not change with the increase of NPL 7 The mechanical withdrawal reflex threshold of mice decreased with the increase of NGF injection dose. Figure 5D, E). Similarly, the results of the hot plate test of the paw withdrawal latency of mice in different groups were consistent with the analysis trend of the Von Frey analgesia instrument ( Figure 5 FJ). These results indicate that injection of NPL 7 It does not cause animals to have a hypersensitive reaction to pain, while injection of NGF will cause animals to have a severe pain reaction. 7 It can overcome the pain response caused by NGF administration.

[0061] The current type of disease being treated is peripheral nerve injury, and will subsequently be expanded to the treatment of neurological diseases such as spinal cord injury, craniocerebral trauma, neonatal hypoxic-ischemic encephalopathy, and neurodegenerative diseases.

Claims

1. A painless nerve growth factor-like peptide, It is characterized in that The amino acid sequence of the pain-free nerve growth factor-like peptide is shown in SEQ ID NO.1-7.

2. The painless nerve growth factor-like peptide according to claim 1, It is characterized in that The amino acid sequence of the pain-free nerve growth factor-like peptide is shown in SEQ ID NO.

7.

3. The pain-free nerve growth factor-like peptide of claim 1, It is characterized in that It can be obtained by any one of solid phase synthesis, liquid phase polypeptide synthesis, genetic engineering or fermentation.

4. The pain-free nerve growth factor-like peptide according to claim 3, It is characterized in that In the process of obtaining pain-free nerve growth factor-like peptides by solid phase synthesis, the equivalent of each amino acid is between 2-5.

5. The pain-free nerve growth factor-like peptide according to claim 3, It is characterized in that The synthesis of painless nerve growth factor-like peptides by genetic engineering requires a nucleic acid molecule, wherein the nucleic acid molecule is used to encode an amino acid sequence as shown in any one of SEQ ID NO.1-7.

6. A recombinant plasmid, It is characterized in that The recombinant plasmid contains the nucleic acid molecule according to any one of claim 6.

7. A transformant, It is characterized in that The transformant comprises the nucleic acid molecule according to claim 6 or the recombinant plasmid according to claim 6.

8. The transformant according to claim 7, It is characterized in that The transformant is Escherichia coli.

9. A drug, It is characterized in that include: The pain-free nerve growth factor-like peptide according to claim 1 or 2; as well as Pharmaceutically acceptable adjuvants.

10. The transformant according to claim 9, It is characterized in that The mass concentration of the pain-free nerve growth factor analog peptide in the drug is 5 ng / mL to 50 μg / mL.

Citation Information

Patent Citations

  • CHO (Chinese Hamster Ovary) cell strain of efficiently-expressed recombinant human nerve growth factor and construction method thereof

    CN102586190A

  • Nerve growth factor mutant

    CN109153709A

  • Polypeptide AAMP and application thereof in analgesia and anti-inflammation

    CN119320425A

  • Cyclized and linear therapeutic peptides

    WO1991017181A1